PMID- 37357817
OWN - NLM
STAT- MEDLINE
DCOM- 20230901
LR  - 20230901
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 202
IP  - 5
DP  - 2023 Sep
TI  - Additional lesions identified by genomic microarrays are associated with an 
      inferior outcome in low-risk chronic lymphocytic leukaemia patients.
PG  - 953-959
LID - 10.1111/bjh.18946 [doi]
AB  - We explored the relevance of genomic microarrays (GM) in the refinement of 
      prognosis in newly diagnosed low-risk chronic lymphocytic leukaemia (CLL) 
      patients as defined by isolated del(13q) or no lesions by a standard 4 probe 
      fluorescence in situ hybridization (FISH) analysis. Compared to FISH, additional 
      lesions were detected by GM in 27 of the 119 patients (22.7%). The concordance 
      rate between FISH and GM was 87.4%. Discordant results between cytogenetic 
      banding analysis (CBA) and GM were observed in 45/119 cases (37.8%) and were 
      mainly due to the intrinsic characteristics of each technique. The presence of 
      additional lesions by GM was associated with age > 65 years (p = 0.047), advanced 
      Binet stage (p = 0.001), CLL-IPI score (p < 0.001), a complex karyotype 
      (p = 0.004) and a worse time-to-first treatment in multivariate analysis 
      (p = 0.009). Additional lesions by GM were also significantly associated with a 
      worse time-to-first treatment in the subset of patients with wild-type TP53 and 
      mutated IGHV (p = 0.025). In CLL patients with low-risk features, the presence of 
      additional lesions identified by GM helps to identify a subset of patients with a 
      worse outcome that could be proposed for a risk-adapted follow-up and for early 
      treatment including targeted agents within clinical trials.
CI  - (c) 2023 The Authors. British Journal of Haematology published by British Society 
      for Haematology and John Wiley & Sons Ltd.
FAU - Rigolin, Gian Matteo
AU  - Rigolin GM
AUID- ORCID: 0000-0002-8370-5190
AD  - Hematology Section, St. Anna University Hospital, Ferrara, Italy.
FAU - Traversa, Alice
AU  - Traversa A
AD  - Department of Experimental Medicine, Sapienza University, Rome, Italy.
FAU - Caputo, Viviana
AU  - Caputo V
AD  - Department of Experimental Medicine, Sapienza University, Rome, Italy.
FAU - Del Giudice, Ilaria
AU  - Del Giudice I
AD  - Hematology, Department of Translational and Precision Medicine, Sapienza 
      University, Rome, Italy.
FAU - Bardi, Antonella
AU  - Bardi A
AD  - Hematology Section, St. Anna University Hospital, Ferrara, Italy.
FAU - Saccenti, Elena
AU  - Saccenti E
AD  - Hematology Section, St. Anna University Hospital, Ferrara, Italy.
FAU - Raponi, Sara
AU  - Raponi S
AUID- ORCID: 0000-0001-9438-0355
AD  - Hematology, Department of Translational and Precision Medicine, Sapienza 
      University, Rome, Italy.
FAU - Ilari, Caterina
AU  - Ilari C
AD  - Hematology, Department of Translational and Precision Medicine, Sapienza 
      University, Rome, Italy.
FAU - Cafforio, Luciana
AU  - Cafforio L
AD  - Hematology, Department of Translational and Precision Medicine, Sapienza 
      University, Rome, Italy.
AD  - GenomeUp S.r.l., Rome, Italy.
FAU - Giovannetti, Agnese
AU  - Giovannetti A
AD  - Clinical Genomics Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, S. 
      Giovanni Rotondo, Italy.
FAU - Pizzuti, Antonio
AU  - Pizzuti A
AD  - Department of Experimental Medicine, Sapienza University, Rome, Italy.
FAU - Guarini, Anna
AU  - Guarini A
AD  - Department of Molecular Medicine, Sapienza University, Rome, Italy.
FAU - Foa, Robin
AU  - Foa R
AD  - Hematology, Department of Translational and Precision Medicine, Sapienza 
      University, Rome, Italy.
FAU - Cuneo, Antonio
AU  - Cuneo A
AD  - Hematology Section, St. Anna University Hospital, Ferrara, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230626
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
SB  - IM
MH  - Humans
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell/pathology
MH  - In Situ Hybridization, Fluorescence
MH  - Prognosis
MH  - Risk Factors
MH  - Genomics
OTO - NOTNLM
OT  - arrays
OT  - chronic lymphocytic leukaemia
OT  - genomic complexity
OT  - prognosis
EDAT- 2023/06/26 06:42
MHDA- 2023/09/01 06:43
CRDT- 2023/06/26 05:28
PHST- 2023/05/31 00:00 [revised]
PHST- 2023/03/29 00:00 [received]
PHST- 2023/06/07 00:00 [accepted]
PHST- 2023/09/01 06:43 [medline]
PHST- 2023/06/26 06:42 [pubmed]
PHST- 2023/06/26 05:28 [entrez]
AID - 10.1111/bjh.18946 [doi]
PST - ppublish
SO  - Br J Haematol. 2023 Sep;202(5):953-959. doi: 10.1111/bjh.18946. Epub 2023 Jun 26.